Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Sonrgy in Licensing Agreement with UC San Diego for Drug Delivery Nanotech

By Doris Mendieta
Posted on 17 Feb 2014
Sonrgy, Inc. (San Diego, CA, USA), a biotechnology company developing focused drug delivery technologies, has obtained an exclusive license agreement with the University of California (UC; USA) for the company’s core technology, an ultrasound-sensitive drug delivery platform.

The agreement gives the company the sole rights to develop and market the technology worldwide. Protecting the basic technology will establish a significant barrier to potential competitors, and is a vital step towards bringing the platform to the clinic.

Based on research conducted in the lab of Prof. Sadik Esener at the UC San Diego Moores Cancer Center (USA), “the SonRx technology addresses longstanding challenges related to stability and controlled release in nanoscale drug delivery,” stated Dr. Michael Benchimol, Sonrgy’s chief technology officer. “We are excited to initiate the next steps of its commercial development.”

Sonrgy is a preclinical stage biotechnology company that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy’s tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focused beam of ultrasound. These carriers convey drugs directly at the tumor cell sites, avoiding the many serious side effects of toxic chemotherapy circulating in the blood stream.

Nanocarriers can deliver chemotherapy before surgery to reduce tumor size, after surgery to prevent recurrence, and in settings when surgery cannot block tumor growth. This distinctive approach to delivering chemotherapy can be applied to many tumors and it enables a more intensive treatment of the cancer, potentially optimizing effectiveness while reducing harmful effects on the rest of the body.

Related Links:

University of California, San Diego Moores Cancer Center
Sonrgy



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.